Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Boehringer Ingelheim and Zealand Pharma have kicked ... consultant in metabolic medicine at University College in Dublin in Ireland, who was the principal investigator of the phase 2 trial.

Commenting on the Jardiance decision, Dr Christoph Zehendner, medical director of Boehringer Ingelheim UK and Ireland, noted that HF with mildly reduced and preserved ejection fraction represents ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

The trial has shown that treatment can "achieve control of the disease but not a cure," Carel le Roux, MD, PhD, of University ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Novo would not be the first pharma major to run contract manufacturing operations serving rivals, as Pfizer (PFE.N), opens new tab and Boehringer Ingelheim ... Ireland's fiscal fortunes suddenly ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...